Market analysis and insights:
It is projected that the global market for cell line development will reach US$ 5.09 billion in 2023 and increase at a compound annual growth rate (CAGR) of 7.10% from 2023 to 2033. By the conclusion of the above mentioned forecast period (2033), the cell line development market is expected to achieve a market value of US$10.08 billion. The industry has a US$4.6 billion market value in 2022.
.jpg
"The Global Cell Line Development Market 2023-2033 (USD Billion)")
The increased demand for monoclonal antibodies is seen as a major driving factor in the market's expansion. Furthermore, an increase in vaccine production around the world is another factor driving market expansion.
Cell Line Development Market Market Scope :
| Metrics | Details |
| Base Year | 2023 |
| Historic Data | 2018-2022 |
| Forecast Period | 2024-2032 |
| Study Period | 2018-2032 |
| Forecast Unit | Value (USD) |
| Revenue forecast in 2033 | USD 10.08 Billion |
| Growth Rate | CAGR of 7.10% during 2021-2033 |
| Segment Covered | By Product, By Source, By Type, By Application, Regions |
| Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
| Key Players Profiled | Culture Collection, Lonza Group AG, Thermo Fisher Scientific, GE Healthcare, Sigma-Aldrich Corporation, Selexia SA, European Collection Of Cell Culture, Corning, WuXi AppTec, Sartoriou, others |
Market Definition
Cell line development is the procedure of generating cell lines that can be used to produce therapeutic biologics or other desired proteins.
Cell line formation is a complicated and time-consuming procedure that is required for the creation of medicinal biologics and other vital proteins.
It enables scientists to mass-produce a desired protein or compound. It enables scientists to manipulate protein or molecule attributes such as expression level, purity, and stability. It enables scientists to make the protein or molecule in a repeatable manner.
Key Market Segmentation:
Insights on Type:
The Bioreactor is growing at the fastest growth rate
During the forecast period, the bioreactor sector of the global cell line development market is predicted to grow at the fastest CAGR. Bioreactors are devices that allow cells to be cultured in a controlled environment. They give the nutrients, growth chemicals, and temperature that cells require to thrive and reproduce.
The increasing need for therapeutic biologics is driving the expansion of the bioreactor segment. Therapeutic biologics are proteins produced by cells, and bioreactors are required for their manufacture. As the demand for medicinal biologics develops, so will the demand for bioreactors.
Furthermore, developments in cell culture technologies are boosting the bioreactor segment. High-throughput screening and other cell culture techniques are making it easier to identify and select cells suitable for the synthesis of therapeutic biologics. As a result, new and improved bioreactors that are better suited for the manufacture of these products are being developed.
The surgical equipment section, in addition to the fitness equipment segment, is predicted to develop during the forecast period. This is due to an increase in the demand for minimally intrusive weight loss procedures. These techniques are less intrusive than standard weight loss surgery and need less time to recuperate.
Insights on Application:
The Bioproduction Segment is boosting
The utilisation of cells to manufacture therapeutic biologics such as vaccines, antibodies, and enzymes is known as bioproduction. Cell lines are critical in bioproduction because they provide a constant and scalable source of cells for the manufacture of these products.
The increasing need for therapeutic biologics is driving the expansion of the bioproduction segment. Therapeutic biologics are rapidly being used to treat a wide range of ailments, including cancer, autoimmune disorders, and infectious diseases. As the demand for these items develops, so will the demand for cell lines for bioproduction.
Furthermore, developments in cell culture technologies are boosting the bioproduction market. High-throughput screening and other cell culture techniques are making it easier to identify and select cells suitable for the synthesis of therapeutic biologics. As a result, new and enhanced cell lines that are better suited for bioproduction are being developed.
Insights on Region Analysis:
The North America renders Ample Financing Opportunities
In terms of market share, North America accounted for 38.20% of the global market for cell line development in 2022. due to the growing popularity of cell culture techniques and their benefits, which include high productivity and cost effectiveness. The drivers driving the market expansion are the region's relatively higher healthcare spending levels, the availability of a sophisticated healthcare infrastructure service, the rising need for biologics, and expanding awareness of cell therapy.
Company Profiles:
These companies have been primarily focusing on strategies like new product development, mergers and acquisitions, collaborations, agreements, and alliances in order to gain a competitive edge in the market.
Culture Collection, Lonza Group AG, Thermo Fisher Scientific, GE Healthcare, Sigma-Aldrich Corporation, Selexia SA, European Collection Of Cell Culture, Corning, WuXi AppTec, Sartoriou, others dominate the Global Cell Line Development market.
COVID-19 Impact and Market Status
Negative impact on market
The disruption of the supply chain has been one of the most important effects of the Covid-19 epidemic on the cell line development sector. Because of the epidemic, there have been widespread delays in the shipment of supplies, making it difficult for cell line development firms to receive the ingredients they require. This has increased the expense of cell line creation while also making it more difficult for corporations to achieve deadlines.
The COVID-19 epidemic has also slowed research and development efforts. Many research laboratories have had to close or operate at a reduced capacity, slowing the generation of new cell lines. This is a significant setback for the cell line development industry.
Regardless of these obstacles, the cell line development industry is likely to rebound in the future years. The demand for therapeutic biologics is likely to rise further, driving up the demand for cell line development services. Furthermore, the development of novel cell line technologies is projected to enable the generation of new cell lines easier and faster, helping to offset some of the obstacles posed by the COVID-19 pandemic.
Latest Trends and Innovation:
• Lonza: Lonza announced the opening of a new Cell Line Development Centre in Singapore in 2021. The centre will be outfitted with cutting-edge equipment and technology and will concentrate on the generation of cell lines for the manufacturing of medicinal biologics.
• Thermo Fisher Scientific: Cell Line Factory was acquired by Thermo Fisher Scientific in 2022. Cell Line Factory is a leading provider of cell line development services, and Thermo Fisher Scientific will benefit from the acquisition by expanding its cell line development capabilities.
• WuXi AppTec: WuXi AppTec announced the release of its new Cell Line Development Platform in 2022. The platform is intended to assist reduce the time and expense of producing new cell lines by streamlining the cell line development process.
• Sartorius AG announced the introduction of their innovative Cell Banking Service in 2023. The service offers customers a turnkey solution for cell line banking and will help to assure the long-term stability of cell lines.
• Merck KGaA: Merck KGaA announced the release of its new Cell Line Development Suite in 2023. The suite provides a complete set of tools and services for developing cell lines for a wide range of applications.
Significant Growth Factors:
From 2023 to 2033, the global cell line development market is predicted to increase at an 7.10% CAGR. A variety of factors are driving market expansion, including:
Increasing demand for therapeutic biologics: Therapeutic biologics are proteins produced by cells, and cell lines are required for their manufacture. The increased prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases is likely to increase demand for therapeutic biologics in the future years.
Advances in cell line technology: Significant advances in cell line technology have occurred in recent years, making it easier and faster to produce new cell lines. These developments include the creation of new cell culture conditions, transfection procedures, and gene editing approaches.
Government regulations: The development and usage of cell lines is strictly regulated in many nations. These rules are intended to assure the safety and effectiveness of cell-based products. The presence of these laws is also propelling the cell line development industry forward.
Growing awareness of the benefits of cell line technology: Pharmaceutical companies and other research organisations are becoming more aware of the benefits of cell line technology. Cell lines have a wide range of applications, including the manufacture of therapeutic biologics, the discovery of new medications, and the testing of innovative medical devices.
Restraining Factors:
Due to the necessity for specialised equipment and personnel, the cost of establishing a new cell line can be expensive. Small and medium-sized businesses may find it difficult to enter the market as a result of this.
The lengthy development time: Because of the requirement to screen and select cells, optimise culture conditions, and evaluate the cell line's stability, developing a new cell line might take several years. This can make bringing new items to market fast difficult.
Contamination of cell lines: Cell lines can get contaminated with other cells or microbes, resulting in the creation of impure or contaminated products. This can endanger patients' safety.
The absence of uniform regulations: There are no standardised regulations governing cell line generation and use. This can make ensuring the safety and efficacy of cell-based products problematic.
Frequently Asked Questions (FAQ) :
The market value of cell line development market in 2032 was US$10.08 billion.
The cell line development market is growing at a CAGR of 7.10% during the forecast period
North America dominated the market for cell line development market and accounted for the largest revenue share.
The cell line development market is expected to grow with a CAGR of 12.3% in the coming years. The increasing demand for monoclonal antibodies, rising vaccine production, and use of innovative technologies propel the growth of the market. COVID 19 stimulates the growth of healthcare centers. The COVID 19 pandemic has shown huge positive impact on cell line development market.
In the future, the make will face a high degree of competition from its rivals due to entry of the various new market players. Some of the opportunities for the market are low income countries like India and Africa lacking access to basic healthcare and increasing risk of pandemic and communicable diseases. However, in spite of innovative technologies in the market, developing stable and authentic cell lines remains a major challenge of this market.
The international market player will continuously focus on offering technically advanced and low cost innovative products for their customers. Some of the leading players that played a major role in the development of the market are American Type Culture Collection (ATCC), Lonza Group AG, Thermo Fisher Scientific, Inc., GE Healthcare , Sigma-Aldrich Corporation, including others.
Based on type, the cell line development market is classified into six types equipment, media and reagent. The equipment segment is further classified into Biosafety Cabinets, Cell Counters and Viability Systems, incubators, Centrifuges, Bioreactors, Storage Equipment, Automated Systems, Microscopes, Filtration Systems and Others. The equipment segment hold the largest market share in the year 2020. The equipment segment accounts for more than 70% of the total market share. Technological advancement in the area of biotechnology is the major factor responsible for the growth and development. Furthermore, advanced healthcare needs is the second most important factor which leads the growth of the market.
Based on type of cell, the cell line development are classified into primary cell lines, continuous cell lines, hybridomas and recombinant cell lines. The continuous cell lines dominates the global cell line development market. The same segment will grow at the highest CAGR% during the forecasted year. Global demand for the monoclonal antibodies is increasing continuously is the another factor which assist in propelling the growth of the market followed vaccine production across the world.
Based on Application, the cell line development market is classified into bio production, tissue engineering & regenerative medicines, toxicity testing, research and drug discovery. Tissue engineering & regenerative medicines accounts for more 15% of the global market share in the year 2020. The tissue engineering is a branch of biomedical engineering used for organs or tissue to restore the normal biological function. Technological advancement lead to increase the usage of cell line development in tissue engineering.
Based on the source type, the cell line development market is classified into mammalian type and non-mammalian type. Mammalian type segment hold the largest market share in the year 2020. The same segment will grow at the fastest CAGR% during the forecasted year. It is estimated that the mammalian segment accounts for more than 80% of the global market shares in the global cell line development market. The most widely used mammalian cell system is Chinese hamster ovary (CHO) cell culture, which results in antibodies that are glycosylated at asparagine-297 (N297).
The cell line development market is growing rapidly. Despite its demand, each region shows a rapid rise in the research and development. North America seems to dominate the global cell line development market. The United States is the major driver for the North America region. Europe always is known for the prosperous regions in the world, and soon the region will also known for its geriatric population. The rising vaccine production not only in Europe but some countries of Asia Pacific like China, India is considered as one of the major driving factors for the growth of the market. Asia Pacific countries like India and China which together hold 34% of the total world population are also looking for a huge investment in- cell line development market. The recent economic boom of this region coupled with rising per-capita healthcare expenditures is also a major factor. Latin American market is dominated by Brazil and Argentina. Brazil holds more than 62% of the total market shares in 2020.
.png "North America Cell Line Development Market (2020)")